Mirum Pharmaceuticals Inc
NASDAQ:MIRM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.57
46.65
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
Cash from Financing Activities
Mirum Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
Cash from Financing Activities
$336.6m
|
CAGR 3-Years
23%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$2.8B
|
CAGR 3-Years
45%
|
CAGR 5-Years
25%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$6.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$5.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$1.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.5B
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mirum Pharmaceuticals Inc
Glance View
In the competitive landscape of the biopharmaceutical industry, Mirum Pharmaceuticals Inc. has carved a niche for itself by specializing in rare liver diseases, a domain that requires both precision and dedication. Founded with a visionary goal, the company primarily focuses on developing treatments that address serious unmet needs within this sphere. At the heart of its operations is the development of maralixibat, a promising drug targeting progressive familial intrahepatic cholestasis and Alagille syndrome, which are both debilitating liver conditions affecting young patients. By addressing these niche markets, Mirum positions itself uniquely, translating complex science into tangible health outcomes. The company makes its money by navigating the rigorous path of drug development, from clinical trials to receiving regulatory approvals, ultimately transforming these therapies into marketable products. Mirum's business model is interlaced with the high stakes world of pharmaceuticals, where innovation meets exhaustive research and development. Revenue generation is contingent upon both the successful commercialization of its drug pipeline and strategic partnerships, which bolster their market reach and resource agility. By engaging closely with healthcare professionals and leveraging compassionate use and expanded access programs, they not only facilitate early adoption but also fuel the momentum needed for market penetration. Moreover, Mirum's commitment to education and engagement strategies fosters a robust ecosystem that underscores the importance of treating rare diseases. This way, the company not only sells its therapeutics but also creates enduring relationships within the medical community, significantly anchoring its financial and operational standing.
See Also
What is Mirum Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
336.6m
USD
Based on the financial report for Dec 31, 2023, Mirum Pharmaceuticals Inc's Cash from Financing Activities amounts to 336.6m USD.
What is Mirum Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
41%
Over the last year, the Cash from Financing Activities growth was 209%. The average annual Cash from Financing Activities growth rates for Mirum Pharmaceuticals Inc have been 23% over the past three years , 41% over the past five years .
You don't have any saved screeners yet
